IMR Press / FBS / Volume 3 / Issue 3 / DOI: 10.2741/207

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

MicroRNA-122: a therapeutic target for hepatitis C virus (HCV) infection
Show Less
1 Department of Medicine and Medical Specialties, Division of Infectious Diseases, University of Catania, Catania, Italy
2 Department of Microbiology and Immunology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, USA

*Author to whom correspondence should be addressed.


Front. Biosci. (Schol Ed) 2011, 3(3), 1032–1037;
Published: 1 June 2011

Hepatitis C virus infection is the main cause of liver disease worldwide, often leading to chronic hepatitis. Recent studies have demonstrated that miRNA-122, a liver-specific miRNA, is required for HCV replication in hepatocytes by its binding to the 5' UTR of HCV. Down-regulation of miRNA-122 in vitro and in vivo has led to significant inhibition of viral replication. In the present article, we report the major recent findings on the potential therapeutic role of anti-miRNA-122 molecules.

Back to top